

## Overview of CML related sessions at EHA2024 Hybrid Congress

June 13-16, 2024 in Madrid (In-Person and live streamed program)

Time slots	Sessions
<b>CML sessions</b>	
June 13 (Thursday)  8.00 – 9.30 CEST  Room: N103	<b>Hybrid Satellite Symposium:</b> (Supported by Novartis) Beyond responses: Optimizing outcomes from the start of the chronic myeloid leukemia treatment journey  Chair: Timothy Hughes (Australia)  Program: <ul style="list-style-type: none"> <li>• Beyond overall survival and achieving responses: what challenges remain when treating CML? (D. Žáčková, Czech Republic)</li> <li>• Novel treatment approaches: elevating the need for tolerability in treatment innovations (S. Saussele, Germany)</li> <li>• Tolerability as the foundation: optimizing outcomes from the start of the treatment journey (T. Hughes, Australia)</li> <li>• Is it time for tolerability to play a greater role in treatment decisions? (All faculty)</li> </ul>
June 14 (Friday)  8.00 – 9.30 CEST  Room: Hall Dali 2	<b>Education Session:</b> Updates in chronic myeloid leukemia (CML) management  Chair: Delphine Réa (France)  Program: <ul style="list-style-type: none"> <li>• Targeting pathways outside BCR::ABL (M. Copland, UK)</li> <li>• The new treatment paradigms: Improving quality of life in CML (F. Efficace, Italy)</li> <li>• ELN Recommendations 2024 (H. Hjorth-Hansen, Norway)</li> </ul>
June 14 (Friday)	<b>Hematology-in-Focus-Session:</b> Chronic myeloid leukemia (CML)

Time slots	Sessions
9.45 – 10.45 CEST Room: Hall Blanchard	Chair: JWM Janssen (The Netherlands) Program: <ul style="list-style-type: none"> <li>• When are alternative therapeutics indicated? (A. Hochhaus, Germany)</li> <li>• Management of CML patients in countries with limited resources (H. Malhotra, India)</li> <li>• Monitoring of CML patients during and after therapy (N. Cross, UK)</li> </ul>
June 15 (Saturday) 8.00 – 8.45 CEST Room: N105	<b>Thematic debate:</b> Treatment of resistant chronic myeloid leukemia (CML): Advanced line drug therapy vs. allogeneic stem cell transplantation (Allo-SCT) Chair: D. Wolf (Austria) Program: <ul style="list-style-type: none"> <li>• Pro: Advanced line drug therapy (V. García-Gutierrez, Spain)</li> <li>• Pro: Allogeneic stem cell transplantation (Y. Chalandon, Switzerland)</li> <li>• Debate (All speakers)</li> </ul>
June 15 (Saturday) 9.45 – 10.45 CEST Room: Hall Malo	<b>Specialized Working Group Session:</b> ELN-EHA SWG for CML Chair: J Apperley (UK) Program: <ul style="list-style-type: none"> <li>• Protac inhibition of BCR-ABL1 (tbd)</li> <li>• BCL2 family in myeloid malignancies (C. Heckman, Finland)</li> <li>• Potential for stem cell inhibition (D. Vetrie, UK)</li> </ul>
Advocacy & Patient Sessions	
June 14 (Friday) 8.00 – 9.30 CEST	<b>EHA-Patient Joint Symposium – Session 1</b> Program and speakers tbd

Time slots	Sessions
Room: N102	
June 14 (Friday)	<b>EHA-Patient Joint Symposium – Session 2</b>
9.45 – 11.15 CEST	Program and speakers tbd
Room: Hall 102	
<b>Oral Sessions</b>	
June 15 (Saturday)	<b>Oral Session:</b> New diagnostic and prognostic tools for CML
16.30 – 17.45 CEST	Program
Room: Hall Malo	<ul style="list-style-type: none"> <li>• S 165: DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR CHRONIC MYELOID LEUKEMIA IN BLAST PHASE: INSIGHTS FROM THE EUROPEAN LEUKEMIANET BLAST PHASE REGISTRY (Lauseker M)</li> <li>• S166: A MACHINE LEARNING APPROACH IDENTIFIES A 27-GENE TRANSCRIPTOMIC SIGNATURE PREDICTING TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (Nicolini FE)</li> <li>• S167: A NOVEL IMMUNE-RELATED SCORE PREDICTS DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) TREATED UP-FRONT WITH TYROSINE KINASE INHIBITORS (TKI) (Steichen J)</li> <li>• S168: COMBINATORY THERAPY OF PONATINIB AND VENETOCLAX WAS EFFECTIVE IN THE TREATMENT OF ASCIMINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN VIVO (Čuřík N)</li> <li>• S169: A NOVEL CIP2A AND BCL-XL CLINICAL DIAGNOSTIC TOOLKIT TO PREDICT DISEASE PROGRESSION AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA (Lucas C)</li> </ul>
June 16 (Sunday)	<b>Oral Session:</b> Optimization and innovation in CML treatment
11.30 – 12.45	Program:

Time slots	Sessions
CEST Room: Hall N104	<ul style="list-style-type: none"> <li>S170: PONATINIB AND 5-AZACYTIDINE FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA IN MYELOID BLAST CRISIS. RESULTS OF THE PONAZA TRIAL (NCT03895671) (Rouselot P)</li> <li>S171: SUSTRENIM TRIAL: SUSTAINED DEEP MOLECULAR RESPONSE AND TFR RATE IN THE LONG-TERM FOLLOW-UP (Breccia M)</li> <li>S172: IMPROVED TOLERABILITY WITH DASATINIB 5 DAYS COMPARED TO 7 DAYS PER WEEK IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. FINAL RESULTS OF THE DASA HIT TRIAL (La Rosée P)</li> <li>S173: OUTCOMES WITH PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA AND THE T315I MUTATION: 4-YEAR RESULTS FROM THE OPTIC TRIAL (Apperley J)</li> <li>S174: A PHASE 2, RANDOMIZED TRIAL OF RUXOLITINIB IN ADDITION TO BCR::ABL1 TKIS IN CML PATIENTS WITH MOLECULAR EVIDENCE OF DISEASE (SWOG TRIAL S1712) (Sweet K)</li> </ul>
<b>Poster presentations</b>	
June 14 (Friday)  18.00 – 19.00 CEST  Poster Area (Hall 7)	<p><b>Poster Session:</b> Chronic myeloid leukemia – Biology &amp; Translational Research</p> <ul style="list-style-type: none"> <li>P705: C3G DEFICIENCY DELAYS CHRONIC MYELOID LEUKEMIA DEVELOPMENT IN A P210 BCR-ABL1 TRANSGENIC MODEL (Berrocal P et al.)</li> <li>P706: DESIGN AND VALIDATION OF A MASS CYTOMETRY APOPTOTIC PANEL FOR PREDICTING SENSITIVITY OF CHRONIC MYELOID BLAST CELLS CROSS-RESISTANT TO TYROSINE KINASE INHIBITORS TO THE BCL2 INHIBITOR VENETOCLAX (Laznicka A et al)</li> <li>P707: MAKING TKI DISCONTINUATION MORE EFFICIENT IN CHRONIC MYELOID LEUKEMIA: THE ROLE OF CIRCULATING CYTOKINES AND RESIDUAL PRIMITIVE LEUKEMIC CELLS (Bianchini M et al)</li> <li>P708: THE THERAPEUTIC EFFECTS OF CXCL14 ON ACUTE AND CHRONIC MYELOID LEUKEMIA (Dudičová S et al.)</li> <li>P709: MODELING SRSF2/TET2 MUTATIONAL COOPERATIVITY IN CMML DEVELOPMENT</li> </ul>

Time slots	Sessions
	<p>(Alihodzic D et al.)</p> <ul style="list-style-type: none"> <li>P710: KF-1601, A DUAL INHIBITOR BCR::ABL1 AND FLT3, OVERCOMES DRUG RESISTANCE IN FLT3+ BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA (Ahn S et al)</li> </ul>
<p>June 14 (Friday)</p> <p>18.00 – 19.00 CEST</p> <p>Poster Area (Hall 7)</p>	<p><b>Poster Session:</b> Chronic myeloid leukemia - Clinical</p> <ul style="list-style-type: none"> <li>P712: UPDATE OF THE FRENCH STOP IMATINIB STUDY (STIM1) EXTENDED LONG TERM FOLLOW UP (Mahon FX et al.)</li> <li>P713: EUROPEAN LEUKEMIANET MILESTONES AND THEIR PROGNOSTIC RELEVANCE FOR ACHIEVING DEEP MOLECULAR RESPONSE AND TREATMENT-FREE REMISSION IN ROUTINE CARE: RESULTS OF THE GERMAN CML REGISTRY (Kohlbrenner K et al.)</li> <li>P714: TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 657 ITALIAN PATIENTS (Bonuomo V et al.)</li> <li>P715: DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. ELIGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI: THE LABNET CML NATIONAL NETWORK (Breccia M et al.)</li> <li>P716: IMPROVEMENT OF TREATMENT-FREE REMISSION RATE FOLLOWING DISCONTINUATION OF BCR::ABL1 TKI WITH A FASTER INITIAL DECLINE OF BCR::ABL1 TRANSCRIPT AND LONGER TREATMENT DURATION IN CHRONIC MYELOID LEUKEMIA (Lee S et al.)</li> <li>P717: ONE YEAR ANALYSIS OF GROWTH DATA IN NEWLY-DIAGNOSED PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB: RESULTS FROM RESULTS OF PONATINIB AS FRONTLINE THERAPY FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE</li> <li>P718: RESULTS OF PONATINIB AS FRONTLINE THERAPY FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (Haddad F et al.)</li> <li>P719: LOWER-DOSE INITIATING BOSUTINIB IS SAFE AND EFFECTIVE FOR RESISTANT OR INTOLERANT TO PRIOR THERAPY CHRONIC MYELOID LEUKEMIA PATIENTS (BOGI TRIAL): A SINGLE-ARM, MULTICENTER, PHASE II TRIAL (Kimura S et al.)</li> <li>P720: ASC4REAL: EFFICACY AND TOLERABILITY COMPARISON BETWEEN ASCEMBL STUDY, A PHASE 3 RANDOMIZED CLINICAL TRIAL (RCT), AND REAL-WORLD (RW) EXPERIENCE WITH ASCIMINIB IN CML PATIENTS BEYOND 2 TKIS (Khanna A et al.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• P721: CLINICAL EFFICACY OF FIRST-LINE NILOTINIB OR IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA – NATIONWIDE REAL LIFE DATA (Zackova D et al.)</li> <li>• P722: OLVEREMBATINIB OVERCOMES PONATINIB AND ASCIMINIB RESISTANCE IN PATIENTS (PTS) WITH HEAVILY PRETREATED CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH<sup>+</sup> ALL) (Jabbour E et al.)</li> <li>• P723: BCR::ABL1 KINETICS IN CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AFTER PONATINIB VERSUS NILOTINIB TREATMENT FRONT-LINE (Nicolini FE et al.)</li> <li>• P724: TREATMENT PATTERNS AND REAL-WORLD CLINICAL OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED WITH ASCIMINIB IN ONCOLOGY PRACTICES IN THE UNITED STATES (Atallah E et al)</li> <li>• P725: PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS (Perusini MA et al.)</li> <li>• P726: IL10 AND IL15 SIGNIFICANTLY PLUMMETED IN PATIENTS PRESENTING WITH TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME (TWS). PRELIMINARY RESULTS FROM THE « KIWIS » STUDY DESIGNED FOR TWS (Johnson Ansah HA et al.)</li> <li>• P728: ANALYSIS OF FACTORS AFFECTING THE ACQUISITION OF MR4.5 UNDER FIRST-LINE IMATINIB TREATMENT (Huang J et al.)</li> <li>• P729: KRAS MUTATION PREDICTS POOR OUTCOME IN PATIENTS WITH MYELOID BLAST PHASE CHRONIC MYELOID LEUKEMIA RECEIVING THIRD GENERATION TYROSINE KINASE INHIBITORS COMBINED WITH AZACITIDINE (Bao M et al.)</li> <li>• P730: ASCIMINIB AS INITIAL THERAPY FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (ALERTCML) (Atallah E et al.)</li> </ul>
<b>Plenary abstract Session</b>	
<p>June 15 (Saturday)</p> <p>14.45 – 16.15 CEST</p> <p>Hall Picasso</p>	<ul style="list-style-type: none"> <li>• S103: ASCIMINIB (ASC) PROVIDES SUPERIOR EFFICACY AND EXCELLENT SAFETY AND TOLERABILITY VS TYROSINE KINASE INHIBITORS (TKI) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN THE PIVOTAL ASC4FIRST STUDY (Hochhaus A et al)</li> </ul>

Time slots	Sessions
<b>e-Poster Presentations</b>	
Chronic myeloid leukemia – Biology and translational research	<ul style="list-style-type: none"> <li>• P1857: A SENSIBLE AND SPECIFIC AUTOMATED SYSTEM FOR THE DETECTION OF DIFFERENT BCR::ABL1 REARRANGEMENTS IN PHILADELPHIA-POSITIVE LEUKEMIAS AT DIAGNOSIS (Stella S et al.)</li> </ul>
Chronic myeloid leukemia - Clinical	<ul style="list-style-type: none"> <li>• P1858: SOMATIC MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS AFTER TYROSINE KINASE INHIBITORS TREATMENT FAILURE AND IN OPTIMAL RESPONSE (Kuzmina E et al.)</li> <li>• P1859: IMPACT OF MOLECULAR RESPONSE DEPTH AT DISCONTINUATION AS A PROGNOSTIC FACTOR OF SUSTAINED TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS IN THE AST TRIAL (Pavlovsky C et al.)</li> <li>• P1860: COVID-19 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: FINAL RESULTS FROM THE GLOBAL OBSERVATIONAL ICMLF CANDID STUDY (Rea D et al.)</li> <li>• P1861: TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME AND PSYCHOLOGICAL ISSUES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER THERAPY DISCONTINUATION (Yuan M et al.)</li> <li>• P1862: PATIENT REPORTED OUTCOMES IN ADULTS WITH TKI-RESISTANT CHRONIC MYELOID LEUKEMIA RECEIVING OLVEREMBATINIB-THERAPY (Yu L et al.)</li> <li>• P1863: TKI-FREE INTERVAL (TFI) FOR SAFE NAVIGATION OF PLANNED PREGNANCY IN NON-TFR ELIGIBLE FEMALE CML PATIENTS (Kumar S et al.)</li> <li>• S1864: CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH RARE BCR::ABL1 FUSION TRANSCRIPTS (Nie Y et al.)</li> <li>• S1865: ASCIMINIB (ASC) IS WELL TOLERATED IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): INTERIM PHARMACOKINETICS AND SAFETY RESULTS FROM ASC4KIDS (Hijiya N et al.)</li> <li>• S1866: COMPARISON OF EARLY TREATMENT RESPONSE &amp; SAFETY OF LOWER DOSE (70 MG/DAY) VERSUS STANDARD DOSE (100 MG/DAY) OF GENERIC DASATINIB IN CHRONIC PHASE CML: RANDOMIZED CONTROLLED STUDY FROM INDIA (Satadeve P et al.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>S1867: RESULTS OF THERAPY OF ASCIMINIB AND PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH FAILURE TO MORE THAN 2 TYROSINE KINASE INHIBITORS AND / OR BCR::ABL1 T315I MUTATION (Chelysheva E et al.)</li> </ul>
<b>For publication only</b>	
Chronic myeloid leukemia – Biology & Translational research	<ul style="list-style-type: none"> <li>PB2579: IMMUNOLOGICAL BIOMARKERS TO DETERMINE THE TREATMENT SUCCESS ON CML PATIENTS ON DASATINIB (Ha H et al.)</li> <li>P2580: HIGH ACCURACY AND SENSITIVITY DIGITAL REAL-TIME PCR (DRPCR) PLATFORM FOR QUANTITATIVE DETECTION OF BCR::ABL1 TRANSCRIPTS DURING CHRONIC MYELOID LEUKEMIA TREATMENT (Song H-W et al.)</li> <li>PB2581: PERFORMANCE COMPARISON EVALUATION OF ‘1COPY™ PROBE TECHNOLOGY-BASED 1COPY™ BCR::ABL1 QPCR KIT’ FOR QUANTITATIVE DETECTION OF BCR::ABL1 (Bok J et al.)</li> <li>P2582: PROGRESSIVE DOWNREGULATION OF PROLIFERATION/SURVIVAL PATHWAYS OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS VS. 12 MONTHS OF NILOTINIB TREATMENT VS. HEALTHY SUBJECTS (Trojani A et al.)</li> <li>P2583: MUTATIONS IN SIGNALING PATHWAYS IN ASSESSING THE PROGNOSIS OF THE DEVELOPMENT OF BCR::ABL-DEPENDENT RESISTANCE TO TKIS (Kustova D et al)</li> <li>P2584: THE ESTABLISHMENT OF AN EX VIVO DRUG SENSITIVITY SCREENING AND DRUG REPURPOSING PLATFORM USING SOUTH AFRICAN LEUKAEMIA PATIENT SAMPLES (Takundwa M et al.)</li> <li>P2585: MULTIPLE CYTOKINE PROFILING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Aleksandrova P et al.)</li> <li>P2586: MOLECULAR INTERROGATION OF CHRONIC MYELOID LEUKAEMIA PATIENTS WHO FAILED SECOND GENERATION TYROSINE KINASE INHIBITOR USING NEXT GENERATION SEQUENCING (Chong SL et al.)</li> </ul>
Chronic myeloid leukemia - Clinical	<ul style="list-style-type: none"> <li>P2587: CHARACTERISTICS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED WITH ASCIMINIB AFTER ONE PRIOR TYROSINE KINASE INHIBITOR: A REAL-WORLD CHART REVIEW STUDY IN THE US (Atallah E et al.)</li> <li>P2588: PREVALENCE OF ARTERIAL HYPERTENSION AMONG PATIENTS WITH CHRONIC</li> </ul>

Time slots	Sessions
	<p>PHASE CHRONIC MYELOID LEUKEMIA ON PONATINIB THERAPY (Lomaia E et al.)</p> <ul style="list-style-type: none"> <li>• P2589: A 10 YEAR OVERALL SURVIVAL ANALYSIS OF CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS IN A MAJOR HAEMATOLOGY CENTRE IN MALAYSIA : A REAL WORLD ANALYSIS (Bakar Ali Z et al.)</li> <li>• P2590: PROGNOSTIC MARKERS AND TREATMENT RESPONSE ASSESSMENT IN CHRONIC MYELOID LEUKEMIA: INSIGHTS FROM A RETROSPECTIVE STUDY IN TUNISIA (Lakhel S et al.)</li> <li>• P2591: A THREE-YEAR FOLLOW UP : REAL-WORLD STUDY OF ENDING TYROSINE KINASE INHIBITOR IN CHRONIC MYELOID LEUKAEMIA (ENTIC) IN MALAYSIA (Chong S et al.)</li> <li>• P2592: REAL WORLD OUTCOMES FOR PATIENTS WITH CML DIAGNOSED AND TREATED AT A SINGLE INSTITUTION (Rhinehart E et al.)</li> <li>• P2593: DASATINIB INDUCED LYMPHOCYTOSIS IN CHRONIC MYELOID LEUKEMIA PATIENTS- REVIEW OF 46 CASES (Balasubramanian P et al.)</li> <li>• P2594: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF CHRONIC MYELOID LEUKEMIA PATIENTS OF ARMENIA: THE PREDICTIVE VALUES OF THE ELTS AND EUTOS SCORES (Maghakyan H et al.)</li> <li>• P2595: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): UNITED KINGDOM FINDINGS ON BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING (McGregor A et al.)</li> <li>• P2597: EVALUATION OF POST-COVID-19 CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Pagnano K et al.)</li> <li>• P2598: PROGNOSTIC SIGNIFICANCE OF BIOMARKERS OF MYOCARDIAL DAMAGE (MD) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) DURING THERAPY WITH INHIBITORS TYROSINE KINASES (TKIS) (Shnalieva N et al.)</li> <li>• P2599: COMEDICATION OF PROTON PUMP INHIBITORS WITH CRYSTALLINE DASATINIB IN CHRONIC MYELOID LEUKEMIA: COMMONLY OCCURRING AND CAUSING MARKEDLY REDUCED TKI-BIOAVAILABILITY</li> <li>• P2600: TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA: A SINGLE-CENTRE EXPERIENCE IN THE UNITED KINGDOM (Choy A et al.)</li> <li>• P2601: INTERACTION BETWEEN GUT MICROBIOME AND TYROSINE KINASE INHIBITORS IN DEFINING THE CLINICAL OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Fava C et al.)</li> <li>• P2602: ALLELE-SPECIFIC PCR FOR THE MAIN BCR::ABL KINASE DOMAIN MUTATIONS</li> </ul>

Time slots	Sessions
	<p>CONFERRING RESISTANCE TO TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA (Kartashova A et al.)</p> <ul style="list-style-type: none"> <li>• P2603: SECOND TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE PATIENTS: SINGLE CENTER REAL-LIFE EXPERIENCE (D' Adda M et al.)</li> <li>• P2604: ASSESSING THE TREATMENT RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS AFTER NEW COMBINATION TREATMENT (Atef B et al.)</li> <li>• P2605: CARDINAL: A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-OPTIMIZATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF TERN-701 IN CHRONIC MYELOID LEUKEMIA (Jabbour E et al.)</li> </ul>